AcquisitionsNov 9, 2026, 04:26 PM
Amneal Pharmaceuticals Acquires Kashiv BioSciences for $1.3B; Q3 Revenue $863M, Net Loss $(21.7)M
AI Summary
Amneal Pharmaceuticals, Inc. announced the completion of its acquisition of Kashiv BioSciences, LLC for a preliminary purchase price of $1.3 billion. The acquisition, which closed on August 10, 2026, involved cash, equity, and significant contingent consideration. The company also reported its financial results for the nine months ended September 30, 2026, with net revenue increasing by 8.0% to $2.38 billion and net income attributable to Amneal increasing to $98.2 million. The balance sheet reflects a substantial increase in assets and liabilities due to the Kashiv acquisition.
Key Highlights
- Amneal Pharmaceuticals completed the acquisition of Kashiv BioSciences, LLC for a preliminary purchase price of $1.3 billion.
- The acquisition consideration included $266.1 million in cash, $491.6 million in equity, and up to $600 million in contingent milestone and royalty payments.
- Preliminary fair value of assets acquired includes $1.003 billion in intangible assets and $179.5 million in goodwill.
- For the nine months ended September 30, 2026, Amneal's net revenue was $2.38 billion, a 8.0% increase year-over-year.
- Net income attributable to Amneal Pharmaceuticals for the nine months ended September 30, 2026 was $98.2 million, compared to $37.0 million in the prior year period.
- Total assets increased to $5.27 billion as of September 30, 2026, from $3.68 billion as of December 31, 2025, largely due to the acquisition.
- Long-term debt increased to $2.92 billion as of September 30, 2026, from $2.57 billion as of December 31, 2025.
Price Impact
More from AMRX